-
-
Currently, intravenous artesunate for the treatment of severe falciparum malaria is dosed at 0, 12, 24, 48, and 72 hours with a total dose of 12 mg/kg (5-dose regimen).
-
In this issue: Statins and diabetes risk; new treatment guideline for diabetes; new pertussis vaccine recommendation; antibiotics and rhinosinusitis; fluoroquinolones and cystitis; and FDA actions.
-
A retrospective review of pediatric cases of dengue fever was undertaken at a single health center in the Bronx area of New York. Over a 3 ½ year period, eight children with dengue infection were identified.
-
In May 2011, an 8-year-old girl developed sore throat, vomiting, and swallowing difficulties. During two emergency room visits with diffuse abdominal pain, she was given intravenous fluids and diagnosed with a viral illness.
-
Case Summary: A 27- year-old physical education teacher presented with two separate episodes of ill-defined dizziness and mild confusion over a period of one week.
-
Timely recognition and treatment of myocardial infarction (MI) are crucial if we are to achieve optimal outcomes for our patients. Silent ischemia, or the absence of classical symptoms of ischemia, may delay the diagnosis.
-
A new topical preparation for the treatment of head lice has been approved by the FDA. Ivermectin is a macrocyclic lactone antibiotic that has been used orally both on and off label for head lice since 2001.
-
Recent efforts to treat a patient in hospital with acute pneumocystis pneumonia (PCP) were hampered by a lack of available injectable trimethoprim-sulfamethoxazole.
-
This report attempts to catalogue the ballooning number of cases of C difficile infection (CDI) in the United States using available resources, including data collected from the IDSA Emerging Infections Program (which has a catchment area of 111 acute-care hospitals and 310 nursing homes); the 2010 National Health and Safety Network data, which covers 711 acute care hospitals in 28 States; and data derived from 3 CDI prevention programs in 3 different states.
